Brief: Dimerix Says DMX-200 Recommended For Regulatory Approval In COVID-19 Study In India
24/09/2021 03:09
Sept 24 (Reuters) - Dimerix Ltd DXB.AX :
* DMX-200 CLARITY COVID-19 STUDY APPROVAL IN INDIA-DXB.AX
* DMX-200 RECOMMENDED FOR REGULATORY APPROVAL IN COVID-19
STUDY IN
INDIA
* PARTICIPANT RECRUITMENT AND DOSING EXPECTED IN NEXT FEW
WEEKS
Source text for Eikon: ID:nASX5SJqCg
Further company coverage: DXB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions